ClinicalTrials.gg
CompletedNCT02793687EPICAUpdated Feb 24, 2025Results posted

Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy

A Phase 3 interventional study of Mexidol and Placebo in Ischemic Stroke, sponsored by Pharmasoft. Completed at 11 sites in Russian Federation. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Pharmasoft · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Mar 2015, registered May 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Ischemic Stroke with a site in Russian Federation — 6 open to participants now, 6 under way, none of them phase 3. Ischemic Stroke · Russian Federation.

Enrollment
9th of 19
150 · median 120
Started
2015
with 1 other
Phase 3
8 of 28
none open now
Registered
8th of 28
by date
Lead sponsor
2 of 28
Pharmasoft

Among the 28 studies in Ischemic Stroke with a site in Russian Federation, this one is the 9th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2015, is one of 8 in phase 3, and was the 8th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

6 of the 28 studies in Ischemic Stroke with a site in Russian Federation are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Ischemic Stroke with a site in Russian Federation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of long-term sequential therapy with Mexidol® in long-term sequential treatment of patients in the acute and early recovery periods of hemispheric ischemic stroke (IS). This is superiority trial that investigates whether Mexidol® better than placebo.

Read the detailed description

In the course of a clinical study involving patients, the efficacy and safety of prolonged sequential therapy with Mexidol® (solution for intravenous and intramuscular administration / coated tablets) were evaluated compared to placebo in patients with hemispheric ischemic stroke during the acute and early recovery periods. The use of Mexidol® (solution for intravenous and intramuscular administration / coated tablets) and placebo (solution for intravenous and intramuscular administration / coated tablets) was conducted against the background of standard baseline therapy.

Throughout the study, both the investigational drug Mexidol® and the placebo, used alongside baseline therapy, were tolerated satisfactorily. In this clinical study, 37 cases of adverse events (AEs) not meeting the criteria for severity were recorded in 28 patients, along with 4 AEs that were categorized as serious adverse events (SAEs) in 4 patients. Most of the registered AEs required appropriate corrective therapy but did not necessitate other medical interventions and resolved by the end of the patient's participation in the study. According to the researchers, in the majority of recorded AEs, the relationship with the investigational drugs was determined to be absent (no relationship).

When comparing the frequency of registration of both individual AEs and SAEs, no statistically significant differences (p \< 0.05) were found in the frequency of AEs/SAEs in patients after taking the investigational drug (Mexidol®) and the comparison drug (placebo). According to the conducted clinical study, the safety profile of Mexidol® remained unchanged and favorable. No new safety signals were recorded during the course of the study.

The primary endpoint is the results of testing using the modified Rankin Scale (mRS) at the end of the therapy course (in both the investigational and control groups). In the overall population of patients included in the efficacy analysis, positive dynamics were observed in both the Mexidol® group and the placebo group (p \< 0.001): a decrease in the mean scores on the scale throughout the study; a statistically significant difference was also identified between the mean scores on the mRS at visit 5 compared to baseline values (visit 1) in both groups. Additionally, at visit 5, a statistically significant difference was observed between the treatment groups (p = 0.04) regarding the total scores on the modified Rankin Scale: the average score for the Mexidol® group was 1.098 points, while for the placebo group, it was 1.46 points. No statistically significant differences between the groups were found at other visits. The assessment of the change in mRS score from baseline (visit 1) to the end of therapy (visit 5) showed statistically significant differences (p = 0.04) between the treatment groups: in the Mexidol® group, the value was 1.098; in the placebo group, it was 1.460.

Thus, Mexidol® demonstrated greater efficacy compared to placebo when used alongside baseline therapy in patients with hemispheric ischemic stroke during the acute and early recovery period based on the primary efficacy criterion, which is the results of testing using the modified Rankin Scale (mRS) at the end of the therapy course.

Furthermore, the study demonstrated the efficacy of Mexidol® therapy concerning several secondary efficacy endpoints. Mexidol® showed greater efficacy in treating hemispheric ischemic stroke compared to placebo when using the specialized scale for this condition-the NIHSS (National Institutes of Health Stroke Scale). In testing using the Beck Depression Inventory (BDI), the efficacy of Mexidol® regarding cognitive disorders in patients who suffered strokes with concurrent diabetes was also identified.

03

Conditions studied

  • Ischemic Stroke

Keywords

  • Stroke
  • Ischemic Stroke
  • Neuroprotective Agents
  • Nootropic Agents
  • Antioxidants
  • Randomized Controlled Trials as Topic
  • Recovery of Function
  • Mexidol
  • Ethylmethylhydroxypyridine Succinate
  • Brain Ischemia
  • Acute Stroke
  • Acute Cerebrovascular Accident
  • Cerebral Stroke
  • Neuroprotection
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of first-ever hemispheric ischemic stroke (codes ICD-10: I63.0 - I63.9).
  2. Age 18-80 years
  3. The ability to understand the purpose of research, risks associated with the research intervention, obligations and consequences of research participation and their right of withdrawing consent any time during the study.
  4. The time from onset of a stroke \<72 hours.
  5. The Modified Rankin Scale (mRS) score ≥3.
  6. The National Institutes of Health Stroke Scale (NIHSS) score from 5 to 15 points.
  7. The Beck Depression Inventory (BDI) score \<19 points.
  8. The written form (ICF) is signed and personally dated by the participant or by an impartial witness (by a person who is independent of the trial and cannot be unduly influenced by the people involved with the trial and who attends the informed consent process).
  9. Negative pregnancy test for women of childbearing age.
  10. Willingness to use reliable methods of , and/or abstinence, for the duration of therapeutic product exposure.

Exclusion criteria

Exclusion Criteria:

  1. No evidence of clinical diagnosis of first-ever hemispheric ischemic stroke (codes ICD-10: I63.0 - I63.9).
  2. Age \<40 and > 80 years.
  3. The National Institutes of Health Stroke Scale (NIHSS) score is \<5 or >15 points.
  4. Hemorrhagic stroke confirmed with CT/MRI.
  5. Hemorrhagic transformation of ischemic stroke.
  6. Recurrent ischemic stroke.
  7. Parkinson's disease.
  8. Epilepsy.
  9. Demyelinating diseases of central nervous system.
  10. Hereditary and degenerative diseases of the central nervous system.
  11. Infectious diseases of central nervous system in medical history.
  12. Traumatic brain injury with severe neurocognitive impairment in medical history.
  13. Unstable angina pectoris.
  14. The participant had a heart attack within 3 months prior to enrollment.
  15. Heart failure class IV ().
  16. 2nd and 3rd-degree atrioventricular block.
  17. Systemic connective tissue disorders.
  18. (stage III or IV).
  19. Acute surgical pathology
  20. Severe decompensated heart failure/liver disease/kidney disease (including acute or chronic kidney/hepatic failure).
  21. Medical history of oncology diseases, tuberculosis, immunodeficiency disorders, mental disorders or alcohol/drug addiction.
  22. The investigator's decision not to enroll participant due to any severe condition that can be issue of safety or treatment efficacy.
  23. Acute infectious diseases (influenza, SARS, etc.) within 4 weeks prior to enrollment.
  24. Evidence of lactose intolerance, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
  25. Pregnancy or breastfeeding.
  26. Any reason (including mental or physical states) that can affect participant's capability to follow protocol procedures.
  27. The participant (or their relative) is affiliated with the clinical site or Sponsor company.
  28. Participation in another clinical trial within 3 months prior to enrollment.
  29. Evidence of reactions or intolerance associated with ethylmethylhydroxypyridine, succinate drugs or Vitamin B6.
  30. Medical for Mexidol®.
  31. The written form (ICF) is not signed and personally dated by the participant or by an impartial witness.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Mexidol®

    Participants received Mexidol® solution IV 500 mg daily for 10 days, then Mexidol 125 mg orally 1 tablet 3 times a day for 8 weeks.

    Drug: Mexidol

  • Placebo comparator
    Placebo

    Participants received Mexidol Placebo matching Mexidol solution IV 500 mg daily for 10 days, then Mexidol 125 mg orally 1 tablet 3 times a day for 8 weeks.

    Other: Placebo

Interventions

  • 50 mg/ml IV solution, 125 mg tablet

    Also known as: Ethylmethylhydroxypyridine Succinate

  • OtherPlacebo

    Placebo IV solution, Placebo tablet

06

What researchers measure

Primary outcomes

  1. Mean Score of the 6-point Modified Rankin Scale (mRS) at Visit 5 After Completion of the Course of Therapy for Both Arms

    The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. Possible scores range from 0 (no symptoms at all) to 6 (dead) \[6 point scale: min value 0, max value 6, higher scores mean a worse outcome\].

    Time frame: Visit 5 (67-71 Day).

Secondary outcomes

  1. Mean Score of the 15-item The National Institutes of Health Stroke Scale (NIHSS) at Visit 5 After Completion of the Course of Therapy for Both Arms

    The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42 (severe stroke), with the minimum score being a 0 (no stroke symptoms).

    Time frame: Visit 5 (67-71 Day)

  2. Mean Score of the 10-item Barthel Index (BI) at Visit 5 After Completion of the Course of Therapy for Both Arms

    The Barthel Index (BI) is a prominent measure that assesses an individual's ability to perform activities of daily living (ADL) independently, reflecting their mobility and functional capacity. BI evaluates ten specific activities: feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, chair transfer, ambulation, and stair climbing. Each activity is weighted based on the level of assistance required, with scores assigned as follows: 10 (independent), 5 (some assistance), and 0 (dependent). The BI's scoring system favors mobility and continence, resulting in a total score ranging from 0 to 100, where a higher score indicates greater functional independence. The index is widely utilized for assessing functional disability, particularly in rehabilitation settings for stroke patients and individuals with neuromuscular or musculoskeletal disorders, as well as in oncology care.

    Time frame: Time frame: Visit 5 (67-71 Day)

  3. Mean Score of the 21-item Beck Depression Inventory (BDI) at Visit 5 After Completion of the Course of Therapy for Both Arms.

    The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. Each item is scored 0 to 3 points for a total score range of 0 to 63. This range includes interpretation from 0-9 points (as normal condition) to over 30 points (as severe depression).

    Time frame: Visit 5 (67-71 Day)

  4. Mean Score of on the EQ-5D-3L PRO Measure (VAS) at Visit 5 After Completion of the Course of Therapy for Both Arms.

    EQ-5D-3L is a concise, generic patient-reported outcome (PRO) measure of health consisting of five dimensions of health status (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a visual analogue scale (VAS). In the study version was used EQ-5D-3L that contains 3 severity levels for each dimension. The EQ VAS records the participants's self-rated health on a vertical VAS where the endpoints are labelled 'The best health you can imagine' (maximum indicated as 100 scores on VAS) and 'The worst health you can imagine' (minimum indicated as 0 on VAS).

    Time frame: Visit 5 (67-71 Day)

07

Results

Posted Feb 24, 2025

Participant flow

Participants were recruited based on protocol requirements at 11 clinical sites between March 2015 and May 2016. The first participant was enrolled on 6 March, 2015 and the last participant was enrolled on 20 February, 2016.

Participant flow — Overall Study
MilestoneMexidol®Placebo
Started7575
Completed6163
Not completed1412

Outcome measures

PrimaryMean Score of the 6-point Modified Rankin Scale (mRS) at Visit 5 After Completion of the Course of Therapy for Both Arms

The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. Possible scores range from 0 (no symptoms at all) to 6 (dead) \[6 point scale: min value 0, max value 6, higher scores mean a worse outcome\].

Time frame:
Visit 5 (67-71 Day).
Reported as:
Mean · score on a scale
Mean Score of the 6-point Modified Rankin Scale (mRS) at Visit 5 After Completion of the Course of Therapy for Both Arms
score on a scaleMexidol®Placebo
Mean Score of the 6-point Modified Rankin Scale (mRS) at Visit 5 After Completion of the Course of Therapy for Both Arms1.098 ± 0.7681.46 ± 0.947
SecondaryMean Score of the 15-item The National Institutes of Health Stroke Scale (NIHSS) at Visit 5 After Completion of the Course of Therapy for Both Arms

The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42 (severe stroke), with the minimum score being a 0 (no stroke symptoms).

Time frame:
Visit 5 (67-71 Day)
Reported as:
Mean · score on a scale
Mean Score of the 15-item The National Institutes of Health Stroke Scale (NIHSS) at Visit 5 After Completion of the Course of Therapy for Both Arms
score on a scaleMexidol®Placebo (Group 2)
Mean Score of the 15-item The National Institutes of Health Stroke Scale (NIHSS) at Visit 5 After Completion of the Course of Therapy for Both Arms1.689 ± 1.3972.222 ± 1.442
SecondaryMean Score of the 10-item Barthel Index (BI) at Visit 5 After Completion of the Course of Therapy for Both Arms

The Barthel Index (BI) is a prominent measure that assesses an individual's ability to perform activities of daily living (ADL) independently, reflecting their mobility and functional capacity. BI evaluates ten specific activities: feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, chair transfer, ambulation, and stair climbing. Each activity is weighted based on the level of assistance required, with scores assigned as follows: 10 (independent), 5 (some assistance), and 0 (dependent). The BI's scoring system favors mobility and continence, resulting in a total score ranging from 0 to 100, where a higher score indicates greater functional independence. The index is widely utilized for assessing functional disability, particularly in rehabilitation settings for stroke patients and individuals with neuromuscular or musculoskeletal disorders, as well as in oncology care.

Time frame:
Time frame: Visit 5 (67-71 Day)
Reported as:
Mean · score on a scale
Mean Score of the 10-item Barthel Index (BI) at Visit 5 After Completion of the Course of Therapy for Both Arms
score on a scaleMexidol®Placebo
Mean Score of the 10-item Barthel Index (BI) at Visit 5 After Completion of the Course of Therapy for Both Arms96.066 ± 7.80693.571 ± 12.229
SecondaryMean Score of the 21-item Beck Depression Inventory (BDI) at Visit 5 After Completion of the Course of Therapy for Both Arms.

The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. Each item is scored 0 to 3 points for a total score range of 0 to 63. This range includes interpretation from 0-9 points (as normal condition) to over 30 points (as severe depression).

Time frame:
Visit 5 (67-71 Day)
Reported as:
Mean · score on a scale
Mean Score of the 21-item Beck Depression Inventory (BDI) at Visit 5 After Completion of the Course of Therapy for Both Arms.
score on a scaleMexidol®Placebo
Mean Score of the 21-item Beck Depression Inventory (BDI) at Visit 5 After Completion of the Course of Therapy for Both Arms.2.213 ± 2.4912.190 ± 2.693
SecondaryMean Score of on the EQ-5D-3L PRO Measure (VAS) at Visit 5 After Completion of the Course of Therapy for Both Arms.

EQ-5D-3L is a concise, generic patient-reported outcome (PRO) measure of health consisting of five dimensions of health status (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a visual analogue scale (VAS). In the study version was used EQ-5D-3L that contains 3 severity levels for each dimension. The EQ VAS records the participants's self-rated health on a vertical VAS where the endpoints are labelled 'The best health you can imagine' (maximum indicated as 100 scores on VAS) and 'The worst health you can imagine' (minimum indicated as 0 on VAS).

Time frame:
Visit 5 (67-71 Day)
Reported as:
Mean · score on a scale
Mean Score of on the EQ-5D-3L PRO Measure (VAS) at Visit 5 After Completion of the Course of Therapy for Both Arms.
score on a scaleMexidol®Placebo
Mean Score of on the EQ-5D-3L PRO Measure (VAS) at Visit 5 After Completion of the Course of Therapy for Both Arms.83.82 ± 15.49978.175 ± 17.52

Adverse events

Collected over Not less than 71 days for each participant. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mexidol®0/75 (0%)1/75 (1.3%)21/75 (28%)
Placebo0/75 (0%)3/75 (4%)16/75 (21.3%)
Most frequent serious events
Most frequent serious events
EventMexidol®Placebo
Ischaemic strokeNervous system disorders1/751/75
Haemorrhagic strokeNervous system disorders0/751/75
Cholecystitis acuteGastrointestinal disorders0/751/75
Most frequent other events
Showing 10 of 27
Most frequent other events
EventMexidol®Placebo
Back painMusculoskeletal and connective tissue disorders1/754/75
GoutMetabolism and nutrition disorders1/752/75
HeadacheVascular disorders1/752/75
DyslipidaemiaMetabolism and nutrition disorders1/750/75
Hepatic enzyme increasedMetabolism and nutrition disorders1/750/75
Type 2 diabetes mellitusMetabolism and nutrition disorders0/751/75
Depressed level of consciousnessNervous system disorders1/750/75
DizzinessNervous system disorders0/751/75
ArthralgiaMusculoskeletal and connective tissue disorders1/750/75
HypertensionVascular disorders1/750/75

Baseline characteristics

ITT-population was used for description of baseline measures.

Age, Categorical
Age, Categorical(Participants)Mexidol®PlaceboTotal
<=18 years000
Between 18 and 65 years354681
>=65 years402969
Age, Continuous
Age, Continuous(years)Mexidol®PlaceboTotal
Mean63.893 ± 10.24661.52 ± 8.66462.70 ± 9.53
Age, Customized
Age, Customized(Participants)Mexidol®PlaceboTotal
Age, sub-groups — < 60 years273259
Age, sub-groups — 60-75 years364076
Age, sub-groups — 76-90 years12315
Sex: Female, Male
Sex: Female, Male(Participants)Mexidol®PlaceboTotal
Female444488
Male313162
Region of Enrollment
Region of Enrollment(Participants)Mexidol®PlaceboTotal
Russia7575150
08

Study locations

11 sites
  • Tatarstan Republican Clinical Hospital
    Kazan, 410064, Russian Federation
  • Interregional Clinical Diagnostic Center
    Kazan, 420101, Russian Federation
  • Kazan Clinical Hospital № 7
    Kazan, 420103, Russian Federation
  • Research Institute of Experimental and Clinical Medicine
    Novosibirsk, 630117, Russian Federation
  • St. Petersburg Clinical Hospital № 26
    Saint Petersburg, 196247, Russian Federation
  • St. Petersburg Clinical Hospital № 2
    Saint Petersburg, 196354, Russian Federation
  • St. Petersburg "Nikolaevskaya" Hospital
    Saint Petersburg, 198510, Russian Federation
  • Samara Regional Clinical Hospital n.a. V. D. Seredavin
    Samara, 443095, Russian Federation
  • Samara Clinical Hospital № 1 n.a. N. I. Pirogov
    Samara, 443096, Russian Federation
  • City Hospital № 40 of Kurortny District
    Sestroretsk, 197706, Russian Federation
  • Vsevolozhsk Clinical Interdistrict Hospital
    Vsevolozhsk, 188643, Russian Federation
09

References and documents

Publications

  • Stakhovskaya LV, Shamalov NA, Khasanova DR, Melnikova EV, Agafiina AS, Golikov KV, Bogdanov EI, Yakupova AA, Roshkovskaya LV, Lukinykh LV, Lokshtanova TM, Poverennova IE, Shepankevich LA. [Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA)]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(3. Vyp. 2):55-65. doi: 10.17116/jnevro20171173255-65. Russian. PubMed 28665371 ↗
  • Stakhovskaya LV, Mkhitaryan EA, Tkacheva ON, Ostroumova TM, Ostroumova OD. [Efficacy and safety of mexidol across age groups in the acute and early recovery stages of hemispheric ischemic stroke (results of additional sub-analysis of a randomized double blind multicenter placebo-controlled study, in parallel groups trial EPICA)]. Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(8. Vyp. 2):49-57. doi: 10.17116/jnevro202012008249. Russian. PubMed 33016677 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in May 2016, 14 months.

Results were first posted in Feb 2025, 8 years 8 months after primary completion.

Of 165 phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2016
First posted
Jun 8, 2016
StartActual
Mar 6, 2015
Primary completionActual
May 27, 2016
CompletionActual
May 27, 2016
Results first posted
Feb 24, 2025
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02793687
Lead sponsor
Pharmasoft
Responsible party
Sponsor
First posted
Jun 8, 2016
Start date
Mar 6, 2015
Primary completion
May 27, 2016
Completion
May 27, 2016
Results posted
Feb 24, 2025
Last update
Feb 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emoxypine succinate

Start the discussion